Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 149-164 , March 2003

Hormone therapy and venous thromboembolism

  • Roger E Peverill, MBBS, PhD, FRACP (Cardiologist, Senior Lecturer)

      Affiliations

    • Corresponding Author InformationAddress: Cardiology Unit, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia.Tel.: +61-395-9422-42; Fax: +61-395-9422-39.

Received 1 August 2002 ,Accepted 1 September 2003.

References 

  1. Keating NL, Cleary PD, Rossi AS, et al.  Use of hormone replacement therapy by post-menopausal women in the United States. Annals of Internal Medicine. 1999;130:545–553
  2. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. British Medical Journal. 1986;292:526
  3. Poulter NR, Chang CL, Farley TMM, et al.  Venous thromboembolic disease and combined oral contraceptives—results of international multicentre case–control study. Lancet. 1995;346:1575–1582
  4. Boston Collaborative Drug Surveillance Program . Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to post-menopausal estrogen therapy. New England Journal of Medicine. 1974;290:15–19
  5. Petitti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women. Smoking, oral contraceptives, noncontraceptive estrogens, and other factors. Journal of the American Medical Association. 1979;242:1150–1154
  6. Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstetrics and Gynecology. 1979;54:74–79
  7. Devor M, Barrett-Connor E, Renvall M, et al.  Estrogen replacement therapy and the risk of venous thrombosis. American Journal of Medicine. 1992;92:275–282
  8. Daly E, Vessey MP, Hawkins MN, et al.  Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977–980
  9. Jick H, Derby LE, Myers MW, et al.  Risk of hospital admission for idiopathic venous thromboembolism among users of post-menopausal oestrogens. Lancet. 1996;348:981–983
  10. Grodstein F, Stampfer MJ, Goldhaber SZ, et al.  Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996;348:983–987
  11. Daly E, Vessey MP, Painter R, Hawkins MM. Case–control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996;348:1027
  12. Perez Gutthann S, Garcia Rodriguez LA, Castellsague J, Duque Oliart A. Hormone replacement therapy and risk of venous thromboembolism—population based case–control study. British Medical Journal. 1997;314:796–800
  13. Hulley S, Grady D, Bush T, et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in post-menopausal women. Journal of the American Medical Association. 1998;280:605–613
  14. Varas Lorenzo C, Garcia Rodriguez LA, Cattaruzzi C, et al.  Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. American Journal of Epidemiology. 1998;147:387–390
  15. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolism—a population-based case–control study. Thrombosis and Haemostasis. 1999;82:1218–1221
  16. Hoibraaten E, Qvigstad E, Arnesen H, et al.  Increased risk of recurrent venous thromboembolism during hormone replacement therapy—results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis. 2000;84:961–967
  17. Writing Group for the Women's Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association. 2002;288:321–333
  18. The Coronary Drug Project Research Group . The Coronary Drug Project. Findings leading to discontinuation of the 2.5-mg day estrogen group. Journal of the American Medical Association. 1973;226:652–657
  19. van Kesteren PJ, Asscheman H, Megens JA, Gooren LJ. Mortality and morbidity in transsexual subjects treated with cross-sex hormones. Clinical Endocrinology. 1997;47:337–342
  20. Grady D, Wenger NK, Herrington D, et al.  Post-menopausal hormone therapy increases risk for venous thromboembolic disease—the heart and estrogen/progestin replacement study. Annals of Internal Medicine. 2000;132:689–696
  21. The Writing Group for the PEPI Trial . Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in post-menopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. Journal of the American Medical Association. 1995;(273):199–208 published erratum appears in JAMA, 274, 1676)
  22. Herrington DM, Reboussin DM, Brosnihan KB, et al.  Effects of estrogen replacement on the progression of coronary–artery atherosclerosis. New England Journal of Medicine. 2000;343:522–529
  23. Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the US preventive services task force. Annals of Internal Medicine. 2002;136:680–690
  24. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. Journal of Internal Medicine. 1992;232:155–160
  25. Prandoni P, Lensing AW, Cogo A, et al.  The long-term clinical course of acute deep venous thrombosis. Annals of Internal Medicine. 1996;125:1–7
  26. Thromboembolic Risk Factors (THRIFT) Consensus Group . Risk of and prophylaxis for venous thromboembolism in hospital patients. British Medical Journal. 1992;305:567–574
  27. Goldhaber SZ, Grodstein F, Stampfer MJ, et al.  A prospective study of risk factors for pulmonary embolism in women. Journal of the American Medical Association. 1997;277:642–645
  28. Heit JA, Melton LJ, Lohse CM, et al.  Incidence of venous thromboembolism in hospitalized patients vs community residents. Mayo Clinic Proceedings. 2001;76:1102–1110
  29. Heit JA, O'Fallon WM, Petterson TM, et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism—a population-based study. Archives of Internal Medicine. 2002;162:1245–1248
  30. Mosca L, Collins P, Herrington DM, et al.  Hormone replacement therapy and cardiovascular disease—a statement for healthcare professionals from the American heart association. Circulation. 2001;104:499–503
  31. Meade TW, Haines AP, Imeson JD, et al.  Menopausal status and haemostatic variables. Lancet. 1983;i:22–24
  32. Meade TW, Dyer S, Howarth DJ, et al.  Antithrombin III and procoagulant activity: sex differences and effects of the menopause. British Journal of Haematology. 1990;74:77–81
  33. Scarabin PY, Bonithon-Kopp C, Bara L, et al.  Factor VII activation and menopausal status. Thrombosis Research. 1990;57:227–234
  34. Folsom AR, Wu KK, Davis CE, et al.  Population correlates of plasma fibrinogen and factor VII, putative cardiovascular risk factors. Atherosclerosis. 1991;91:191–205
  35. Scarabin PY, Vissac AM, Kirzin JM, et al.  Population correlates of coagulation factor VII. Importance of age, sex, and menopausal status as determinants of activated factor VII. Arteriosclerosis, Thrombosis and Vascular Biology. 1996;16:1170–1176
  36. Balleisen L, Bailey J, Epping PH, et al.  Epidemiological study on factor VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age, gender, body-weight, smoking, alcohol, pill-using, and menopause. Thrombosis and Haemostasis. 1985;54:475–479
  37. Bonithon-Kopp C, Scarabin PY, Darne B, et al.  Menopause-related changes in lipoproteins and some other cardiovascular risk factors. International Journal of Epidemiology. 1990;19:42–48
  38. Gebara OC, Mittleman MA, Sutherland P, et al.  Association between increased estrogen status and increased fibrinolytic potential in the Framingham offspring study. Circulation. 1995;91:1952–1958
  39. Scarabin PY, Plu-Bureau G, Bara L, et al.  Haemostatic variables and menopausal status: influence of hormone replacement therapy. Thrombosis and Haemostasis. 1993;70:584–587
  40. Caine YG, Bauer KA, Barzegar S, et al.  Coagulation activation following estrogen administration to post-menopausal women. Thrombosis and Haemostasis. 1992;68:392–395
  41. Kroon UB, Silfverstolpe G, Tengborn L. The effects of transdermal estradiol and oral conjugated estrogens on haemostasis variables. Thrombosis and Haemostasis. 1994;71:420–423
  42. van Baal WM, Emeis JJ, van der Mooren MJ, et al.  Impaired procoagulant-anticoagulant balance during hormone replacement therapy? A randomized, placebo-controlled 12-week study. Thrombosis and Haemostasis. 2000;83:29–34
  43. Vehkavaara S, Silveira A, Hakala-Ala-Pietila T, et al.  Effects of oral and transdermal estrogen replacement therapy on markers of coagulation, fibrinolysis, inflammation and serum lipids and lipoproteins in postmenopausal women. Thrombosis and Haemostasis. 2001;85:619–625
  44. Scarabin PY, Alhencgelas M, Plubureau G, et al.  Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in post-menopausal women—a randomized controlled trial. Arteriosclerosis, Thrombosis and Vascular Biology. 1997;17:3071–3078
  45. Teede HJ, McGrath BP, Smolich JJ, et al.  Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arteriosclerosis, Thrombosis and Vascular Biology. 2000;20:1404–1409
  46. Saleh AA, Dorey LG, Dombrowski MP, et al.  Thrombosis and hormone replacement therapy in post-menopausal women. American Journal of Obstetcics and Gynecology. 1993;169:1554–1557
  47. Walsh BW, Kuller LH, Wild RA, et al.  Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women. Journal of the American Medical Association. 1998;279:1445–1451
  48. Hoibraaten E, Qvigstad E, Andersen TO, et al.  The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism—results from a randomized, double-blind, clinical trial. Thrombosis and Haemostasis. 2001;85:775–781
  49. Lindberg UB, Crona N, Stigendal L, et al.  A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thrombosis and Haemostasis. 1989;61:65–69
  50. Boschetti C, Cortellaro M, Nencioni T, et al.  Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women. Thrombosis Research. 1991;62:1–8
  51. Lobo RA, Pickar JH, Wild RA, The menopause study group , et al.  Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. Obstetrics and Gynecology. 1994;84:987–995
  52. Nozaki M, Ogata R, Koera K, et al.  Changes in coagulation factors and fibrinolytic components of post-menopausal women receiving continuous hormone replacement therapy. Climacteric. 1999;2:124–130
  53. Gottsater A, Rendell M, Hulthen UL, et al.  Hormone replacement therapy in healthy post-menopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors. Journal of Internal Medicine. 2001;249:237–246
  54. van Wersch JW, Ubachs JM, van den Ende A, van Enk A. The effect of two regimens of hormone replacement therapy on the haemostatic profile in post-menopausal women. European Journal of Clinical Chemistry and Clinical Biochemistry. 1994;32:449–453
  55. Crosignani PG, Cortellaro M, Boschetti C. Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate—a 1-year, double-blind, placebo-controlled study. Thrombosis and Haemostasis. 1996;75:476–480
  56. Sporrong T, Mattsson LA, Samsioe G, et al.  Haemostatic changes during continuous oestradiol–progestogen treatment of post-menopausal women. British Journal of Obstetrics and Gynaecology. 1990;97:939–944
  57. Samsioe G, Larsen S & Arce J-C. Haemostasis profile associated with continuous combined 1mg 17beta-estradiol and low doses of norethisterone acetate. 9th Annual Meeting of the North American Menopause Society, Toronto, Canada; 1998 (abstract).
  58. Peverill RE, Teede HJ, Smolich JJ, et al.  Effect of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII. Clinical Science. 2001;101:93–99
  59. Kessler CM, Szymanski LM, Shamsipour Z, et al.  Estrogen replacement therapy and coagulation—relationship to lipid and lipoprotein changes. Obstetrics and Gynecology. 1997;89:326–331
  60. Chen FP, Lee N, Soong YK, Huang KE. Comparison of transdermal and oral estrogen–progestin replacement therapy: effects on cardiovascular risk factors. Menopause. 2001;8:347–352
  61. Gilabert J, Estelles A, Cano A, et al.  The effect of estrogen replacement therapy with or without progestogen on the fibrinolytic system and coagulation inhibitors in post-menopausal status. American Journal of Obstetrics and Gynecology. 1995;173:1849–1854
  62. Nabulsi AA, Folsom AR, White A, The atherosclerosis risk in communities study investigators , et al.  Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. New England Journal of Medicine. 1993;328:1069–1075
  63. Kroon UB, Tengborn L, Rita H, Backstrom AC. The effects of transdermal oestradiol and oral progestogens on haemostasis variables. British Journal of Obstetrics and Gynaecology. 1997;104:32–37
  64. Svensson PJ, Dahlback B. Resistance to activated protein C as a basis for venous thrombosis. New England Journal of Medicine. 1994;330:517–522
  65. Zoller B, Svensson PJ, He XH, Dahlback B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. Journal of Clinical Investigation. 1994;94:2521–2524
  66. Marcucci R, Abbate R, Fedi S, et al.  Acquired activated protein C resistance in postmenopausal women is dependent on factor VIII:c levels. American Journal of Clinical Pathology. 1999;111:769–772
  67. Rosing J, Tans G, Nicolaes GA, et al.  Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. British Journal of Haematology. 1997;97:233–238
  68. Tans G, Curvers J, Middeldorp S, et al.  A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways. Thrombosis and Haemostasis. 2000;84:15–21
  69. Lowe GDO, Rumley A, Woodward M, et al.  Activated protein C resistance and the FV: R(506)Q mutation in a random population sample—associations with cardiovascular risk factors and coagulation variables. Thrombosis and Haemostasis. 1999;81:918–924
  70. Hoibraaten E, Mowinckel MC, de Ronde H, et al.  Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial. British Journal of Haematology. 2001;115:415–420
  71. Douketis JD, Gordon M, Johnston M, et al.  The effects of hormone replacement therapy on thrombin generation, fibrinolysis inhibition, and resistance to activated protein C: prospective cohort study and review of the literature. Thrombosis Research. 2000;99:25–34
  72. Demirol A, Baykal C, Kirazli S, Ayhan A. Effects of hormone replacement on hemostasis in spontaneous menopause. Menopause. 2001;8:135–140
  73. Folsom AR. Epidemiology of fibrinogen. European Heart Journal. 1995;16(supplement A):21–24
  74. Andersen LF, Gram J, Skouby SO, Jespersen J. Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. American Journal of Obstetrics and Gynecology. 1999;180:283–289
  75. Frohlich M, Schunkert H, Hense HW, et al.  Effects of hormone replacement therapies on fibrinogen and plasma viscosity in postmenopausal women. British Journal of Haematology. 1998;100:577–581
  76. Conard J, Gompel A, Pelissier C, et al.  Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. Fertility and Sterility. 1997;68:449–453
  77. Whiteman MK, Cui YD, Flaws JA, et al.  Low fibrinogen level: a predisposing factor for venous thromboembolic events with hormone replacement therapy. American Journal of Hematology. 1999;61:271–273
  78. Segui R, Estelles A, Mira Y, et al.  PAI-1 promoter 4G/5G genotype as an additional risk factor for venous thrombosis in subjects with genetic thrombophilic defects. British Journal of Haematology. 2000;111:122–128
  79. Koh KK, Mincemoyer R, Bui MN, et al.  Effects of hormone-replacement therapy on fibrinolysis in post-menopausal women. New England Journal of Medicine. 1997;336:683–690
  80. Koh KK, Horne MK, Csako G, et al.  Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women. American Journal of Cardiology. 1999;83:466–469
  81. Rosendaal FR, Vessey M, Rumley A, et al.  Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. British Journal of Haematology. 2002;116:851–854
  82. Vandenbroucke JP, Koster T, Briet E, et al.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet. 1994;344:1453–1457
  83. Martinelli I, Taioli E, Bucciarelli P, et al.  Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arteriosclerosis, Thrombosis and Vascular Biology. 1999;19:700–703
  84. Psaty BM, Smith NL, Lemaitre RN, et al.  Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in post-menopausal women. Journal of the American Medical Association. 2001;285:906–913
  85. Vandenbroucke JP, Vandermeer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden—should we screen oral contraceptive users and pregnant women. British Medical Journal. 1996;313:1127–1130
  86. Herrington DM, Vittinghoff E, Howard TD, et al.  Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arteriosclerosis, Thrombosis and Vascular Biology. 2002;22:1012–1017
  87. Gass M, Liu J, Rebar RW. The effect of low-dose conjugated equine estrogens and cyclic MPA on bone density. Maturitas. 2002;41:143–147
  88. Loh FH, Chen LH, Yu SL, Jorgensen LN. The efficacy of two dosages of a continuous combined hormone replacement regimen. Maturitas. 2002;41:123–131
  89. Gambacciani M, Ciaponi M, Cappagli B, Genazzani AR. Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in post-menopausal women. American Journal of Obstetrics and Gynecology. 2001;185:1180–1185
  90. Peverill RE, Davis S, Goldstat R et al. Comparison of effects of pravastatin and combined hormone replacement therapy on coagulation and fibrinolysis. 48th Annual Scientific Meeting of the Cardiac Society of Australia and New Zealand August; 2000 (abstract).
  91. Hoibraaten E, Os I, Seljeflot I, et al.  The effects of hormone replacement therapy on hemostatic variables in women with angiographically verified coronary artery disease: results from the estrogen in women with atherosclerosis study. Thrombosis Research. 2000;98:19–27
  92. The Writing Group for the Estradiol Clotting Factors Study . Effects on haemostasis of hormone replacement therapy with transdermal estradiol and oral sequential medroxyprogesterone acetate: a 1-year, double-blind, placebo-controlled study. Thrombosis and Haemostasis. 1996;75:476–480
  93. Walker ID, Davidson JF, Richards A, et al.  The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in post-menopausal women. Thrombosis and Haemostasis. 1985;53:303–305
  94. Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas. 1987;(supplement 1):67–72
  95. Parkin DE, Smith D, Al Azzawi F, et al.  Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas. 1987;9:95–101
  96. Winkler UH, Altkemper R, Kwee B, et al.  Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertility and Sterility. 2000;74:10–19
  97. Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. British Journal of Clinical Pharmacology. 1998;45:608–612
  98. Fisher B, Costantino JP, Wickerham DL, et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute. 1998;90:1371–1388
  99. Guerrieri-Gonzaga A, Galli A, Rotmensz N, Decensi A. The Italian breast cancer prevention trial with tamoxifen: findings and new perspectives. Annals of the New York Academy of Sciences. 2001;949:113–122
  100. Veronesi U, Maisonneuve P, Costa A, et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomized trial among hysterectomized women. Italian tamoxifen prevention study. Lancet. 1998;352:93–97
  101. Powles T, Eeles R, Ashley S, et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomized chemoprevention trial. Lancet. 1998;352:98–101
  102. Cummings SR, Eckert S, Krueger KA, et al.  The effect of raloxifene on risk of breast cancer in postmenopausal women—results from the MORE randomized trial. Journal of the American Medical Association. 1999;281:2189–2197

PII: S1521-690X(02)00079-9

doi: 10.1016/S1521-690X(02)00079-9

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 17, Issue 1 , Pages 149-164 , March 2003

Article Tools